MedPath

Efficacy of Dialectical Behavior Therapy Versus CAMS-informed Supportive Psychotherapy on Self Harming Behavior

Not Applicable
Completed
Conditions
Suicide
Borderline Personality Disorder
Interventions
Behavioral: CAMS
Behavioral: DBT
Registration Number
NCT01512602
Lead Sponsor
Mental Health Services in the Capital Region, Denmark
Brief Summary

Purpose: The purpose of this study is to investigate the efficacy of Dialectical Behavior Therapy (DBT) versus CAMS (Collaborative Assessment and Management of Suicidality) -informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self behavior and personality traits within the spectrum of borderline personality disorder.

Hypothesis: The hypothesis is 16 weeks of treatment with Dialectical Behavior Therapy (DBT) after a defined manual has a higher efficacy than CAMS-informed supportive psychotherapy on self-harm acts, suicide attempts, suicidal ideation, depressive symptoms, impulsiveness and consumption of hospital services in patients with symptoms within the spectrum of borderline personality disorder (BDP).

Method: The investigators will include 160 patients in the randomized trial to investigate whether 16 weeks of DBT-treatment as a higher efficacy than CAMS-informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self-harm behavior and personality traits within the spectrum of borderline personality disorder. The trial will meet strict criteria for high quality randomized trials, and will hopefully help to establish evidence for the treatment of this patient group at higher risk of later suicide. There will be performed follow up interviews after 16 weeks, 28 weeks and 52 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
108
Inclusion Criteria
  • 18-65 years of age.
  • Newly suicide attempt within one month of the inclusion date.
  • A minimum of two characteristics in the DSM-IV Borderline Personality Disorder (BPD)
  • Informed consent.
Exclusion Criteria
  • Severe depression.
  • Bipolar disorder.
  • Psychosis within the schizophrenic spectrum.
  • Anorexia Nervosa.
  • Substance abuse.
  • Mental retardation.
  • Dementia.
  • Lack of informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CAMSCAMSCollaborative Assessment and Management of Suicidality, CAMS-informed supportive psychotherapy
Dialectical Behavior Therapy DBTDBT16 weeks DBT-treatment
Primary Outcome Measures
NameTimeMethod
Number of repeated self-harming acts including suicide attempts (change in number of self-harming acts).Week 0 (baseline), 17, 28, 52.

This information will be obtained as self-reported and through journal entries.How many acts how has taken place between the different time points in the trial (week 0, 17,28, and 52) to actually quantify the self-harming acts in order to find out if the treatment in the two arms can decrease the numbers of self-harming acts, also long term effect (week 52).

Secondary Outcome Measures
NameTimeMethod
Suicide related behavior.Assessed at baseline, after treatment period (16 weeks), Week 28 and 52 after inclusion.

Measured by Suicide Attempt Self Injury Interview (SASII) and Beck's suicide intent Scale

Depressive symptomsAssessed at baseline, after treatment period (16 weeks), Week 28 and 52 after inclusion

Measured by HDRS-17 and BDI.

Suicidal ideationAssessed at baseline, after treatment period (16 weeks), Week 28 and 52 after inclusion

Measured by Beck's Suididal Ideation Scale (SSI-21)

AngerAssessed at baseline, after treatment period (16 weeks), Week 28 and 52 after inclusion

Measured by State Trait Anger Scale.

Consumptions of services in hospital care.After treatment period (16 weeks), Week 28 and 52 after inclusion

Register based information: Contact with hospital contact with code 4 (self-harm act), or suicide attemp X60-X84, or poisioning by weak analgesia (T39), hypnotics (T52), or psychothopic drugs (T43). Vital status, causes of death, use of bed days and outpatients services.

Severity of borderline personality disorder symptoms.Assessed at baseline, after treatment period (16 weeks), Week 28 and 52 after inclusion

Measured by Zanarini Borderline Personality Scale.

HopelessnessAssessed at baseline, after treatment period (16 weeks), Week 28 and 52 after inclusion.

Measured by Becks Hopelessness Scale.

Self EsteemAssessed at baseline, after treatment period (16 weeks), Week 28 and 52 after inclusion

Measured by Rosenbergs Self esteem Scale (RSE).

ImpulsivityAssessed at baseline, after treatment period (16 weeks), Week 28 and 52 after inclusion

Measured by Barratts Impulsivity Scale (BIS-11)

Trial Locations

Locations (1)

Mental Health Services, Research Unit, Bispebjerg

🇩🇰

Copenhagen NV., Denmark

© Copyright 2025. All Rights Reserved by MedPath